Patents by Inventor Thorsten A. Kirschberg

Thorsten A. Kirschberg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240316025
    Abstract: Provided herein are methods for treating liver disorders, including non-alcoholic steatohepatitis, and symptoms and manifestations thereof, in a patient which utilize, among others, a combination treatment of an FXR agonist and a THR? agonist.
    Type: Application
    Filed: June 3, 2024
    Publication date: September 26, 2024
    Inventors: Martijn FENAUX, Kevin KLUCHER, Christopher T. JONES, Thorsten A. KIRSCHBERG
  • Publication number: 20240300950
    Abstract: Described herein is N-[4-[4-(4-morpholinyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(R)-[(1-oxo-2-propen-1-yl)amino]-1-piperidinyl]methyl]-2-pyridinecarboxamide (Compound A) (Formula I), including crystalline forms, solvates, and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions or pharmaceutical formulations that include the compound, as well as methods of using the compound, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, diabetes, and inflammatory diseases or conditions.
    Type: Application
    Filed: January 30, 2024
    Publication date: September 12, 2024
    Inventors: Satish Goud Puppali, James T. Palmer, Thorsten A. Kirschberg, Angelina Sau Man Wong, Heow Meng Tan, Jay Li, Ming Lin, Ming Gao, Junlu Ding, Shuang Li, Yuyao GU, Hongyan He, Bo Zheng, Yanjing Zhou, Mei You, Yihong Qiu
  • Publication number: 20240262795
    Abstract: Disclosed herein are heterocyclic compounds that inhibit the activity of FLT3. Also described are specific covalent inhibitors of FLT3. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the FLT3 inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of proliferative diseases or conditions, including hematological malignancies and other diseases or conditions dependent on FLT3 activity.
    Type: Application
    Filed: February 13, 2024
    Publication date: August 8, 2024
    Inventors: David Sperandio, Xiaodong Wang, Thorsten A. Kirschberg, James T. Palmer, Thomas Butler, Solomon B. Ungashe, Neil Howard Squires, Nan-Horng Lin, Ravindra B. Upasani, Amna Trinity-Turjuman Adam, Yongli Su, Thu Phan
  • Publication number: 20240254137
    Abstract: The present disclosure relates generally to modulators of Cot (cancer Osaka thyroid) and methods of use and manufacture thereof.
    Type: Application
    Filed: December 11, 2023
    Publication date: August 1, 2024
    Inventors: Elizabeth M. Bacon, Gayatri Balan, Chien-Hung Chou, Christopher T. Clark, Jeromy J. Cottell, Musong Kim, Thorsten A. Kirschberg, John O. Link, Gary Phillips, Scott D. Schroeder, Neil H. Squires, Kirk L. Stevens, James G. Taylor, William J. Watkins, Nathan E. Wright, Sheila M. Zipfel
  • Publication number: 20240124467
    Abstract: Disclosed herein are heterocyclic compounds that inhibit the binding of menin and MLL or MLL fusion proteins. Also described are specific irreversible inhibitors of menin-MLL interaction. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the menin-MLL irreversible inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, leukemia and other diseases or conditions dependent on menin-MLL interaction.
    Type: Application
    Filed: December 16, 2021
    Publication date: April 18, 2024
    Inventors: Thomas Butler, James T. PALMER, Thorsten KIRSCHBERG, Nan-Homg LIN, Hon HUI, Ravindra UPASANI, Solomon B. UNGASHE, David SPERANDIO
  • Patent number: 11945785
    Abstract: Disclosed herein are heterocyclic compounds, for example, according to the following formula and analogs thereof: that inhibit the activity of FLT3. Also described are specific covalent inhibitors of FLT3. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the FLT3 inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of proliferative diseases or conditions, including hematological malignancies and other diseases or conditions dependent on FLT3 activity.
    Type: Grant
    Filed: December 29, 2022
    Date of Patent: April 2, 2024
    Assignee: Biomea Fusion, Inc.
    Inventors: David Sperandio, Xiaodong Wang, Thorsten A. Kirschberg, James T. Palmer, Thomas Butler, Solomon B. Ungashe, Neil Howard Squires, Nan-Horng Lin, Ravindra B. Upasani, Amna Trinity-Turjuman Adam, Yongli Su, Thu Phan
  • Publication number: 20240101536
    Abstract: Provided herein are compounds, preferably compounds inhibiting tyrosine kinase enzymatic activity of a protein selected from Abelson protein (ABL1), Abelson-related protein (ABL2), or a chimeric protein BCR-ABL1, compositions thereof, and methods of their preparation, and methods of inhibiting tyrosine kinase enzymatic activity of a protein selected from Abelson protein (ABL1), Abelson-related protein (ABL2), or a chimeric protein BCR-ABL1, and methods for treating diseases wherein modulation of BCR-ABL1 activity prevents, inhibits, or ameliorates the pathology and/or symptomology of the disease.
    Type: Application
    Filed: June 22, 2023
    Publication date: March 28, 2024
    Inventors: F. Anthony ROMERO, Thorsten A. KIRSCHBERG, Randall HALCOMB, Yingzi XU
  • Publication number: 20240059682
    Abstract: Provided herein are compounds, preferably thyroid hormone receptor beta (THR beta) agonist compounds, compositions thereof, and methods of their preparation, and methods of agonizing THR beta and methods for treating disorders ameliorated by activation of THR beta.
    Type: Application
    Filed: March 2, 2022
    Publication date: February 22, 2024
    Inventors: Thorsten A. KIRSCHBERG, Corey REEVES, Kevin KLUCHER, Martijn FENAUX, Yingzi XU, F. Anthony ROMERO, Randall HALCOMB
  • Patent number: 11905299
    Abstract: The present disclosure relates generally to modulators of Cot (cancer Osaka thyroid) and methods of use and manufacture thereof.
    Type: Grant
    Filed: May 11, 2021
    Date of Patent: February 20, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Elizabeth M. Bacon, Gayatri Balan, Chien-Hung Chou, Christopher T. Clark, Jeromy J. Cottell, Musong Kim, Thorsten A. Kirschberg, John O. Link, Gary Phillips, Scott D. Schroeder, Neil H. Squires, Kirk L. Stevens, James G. Taylor, William J. Watkins, Nathan E. Wright, Sheila M. Zipfel
  • Publication number: 20240000765
    Abstract: Provided herein are methods for treating liver disorders, including non-alcoholic steatohepatitis, and symptoms and manifestations thereof, in a patient which utilize, among others, a combination treatment of an FXR agonist and a THR? agonist.
    Type: Application
    Filed: January 20, 2023
    Publication date: January 4, 2024
    Inventors: Martijn FENAUX, Kevin KLUCHER, Christopher T. JONES, Thorsten A. KIRSCHBERG
  • Publication number: 20230339867
    Abstract: Disclosed herein are heterocyclic compounds that inhibit the activity of FLT3. Also described are specific covalent inhibitors of FLT3. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the FLT3 inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of proliferative diseases or conditions, including hematological malignancies and other diseases or conditions dependent on FLT3 activity.
    Type: Application
    Filed: December 29, 2022
    Publication date: October 26, 2023
    Inventors: David Sperandio, Xiaodong Wang, Thorsten A. Kirschberg, James T. Palmer, Thomas Butler, Solomon B. Ungashe, Neil Howard Squires, Nan-Horng Lin, Ravindra B. Upasani, Amna Trinity-Turjuman Adam, Yongli Su, Thu Phan
  • Publication number: 20230322744
    Abstract: The present application provides compounds that may be used as a glucagon-like peptide-1 receptors (GLP-1R) agonist, or stereoisomers, tautomers, or pharmaceutically acceptable salts of any of the foregoing. Also provided are pharmaceutical compositions containing such compounds, or stereoisomers, tautomers, or pharmaceutically acceptable salts of any of the foregoing. Methods of prepare these compounds and compositions and method of using them to treat or present a disease or a condition mediated by GLP-1R.
    Type: Application
    Filed: August 20, 2021
    Publication date: October 12, 2023
    Inventors: F. Anthony ROMERO, Christopher T. JONES, Martijn FENAUX, Corey REEVES, Thorsten A. KIRSCHBERG, Yingzi XU
  • Publication number: 20230270719
    Abstract: This application relates generally to certain substituted pyrrolizine compounds, and pharmaceutical compositions which inhibit HBV replication, and methods of making and using them.
    Type: Application
    Filed: November 29, 2022
    Publication date: August 31, 2023
    Inventors: Jinfa Du, Joshua A. Kaplan, Thorsten A. Kirschberg, Tetsuya Kobayashi, Scott E. Lazerwith, Rick Andrew Lee, Jonathan William Medley, Michael L. Mitchell, Philip Anthony Morganelli, Hyung-Jung Pyun, Sophia L. Shevick, Neil H. Squires, William J. Watkins
  • Publication number: 20230241071
    Abstract: Provided herein are methods for treating liver disorders, including non-alcoholic steatohepatitis (NASH), and symptoms and manifestations thereof, in a patient which utilize, among others, a combination treatment of an SSAO inhibitor and a THR-? agonist. Also provided are fixed-dose combinations of an SSAO inhibitor and a THR-? agonist for use in treating NASH.
    Type: Application
    Filed: November 11, 2022
    Publication date: August 3, 2023
    Inventors: Martijn FENAUX, Kevin KLUCHER, Christopher T. JONES, Thorsten A. KIRSCHBERG, Yujin WANG
  • Publication number: 20230002407
    Abstract: The present disclosure relates generally to modulators of Cot (cancer Osaka thyroid) and methods of use and manufacture thereof.
    Type: Application
    Filed: May 11, 2021
    Publication date: January 5, 2023
    Inventors: Elizabeth M. Bacon, Gayatri Balan, Chien-Hung Chou, Christopher T. Clark, Jeromy J. Cottell, Musong Kim, Thorsten A. Kirschberg, John O. Link, Gary Phillips, Scott D. Schroeder, Neil H. Squires, Kirk L. Stevens, James G. Taylor, William J. Watkins, Nathan E. Wright, Sheila M. Zipfel
  • Publication number: 20220356177
    Abstract: Provided herein are compounds, preferably thyroid hormone receptor beta (THR beta) agonist compounds, compositions thereof, and methods of their preparation, and methods of agonizing THR beta and methods for treating disorders mediated by THR beta.
    Type: Application
    Filed: September 11, 2020
    Publication date: November 10, 2022
    Inventors: Thorsten A. KIRSCHBERG, Randall HALCOMB, Yingzi XU, F. Anthony ROMERO
  • Publication number: 20220348561
    Abstract: Provided herein are compounds, preferably thyroid hormone receptor beta (THR beta) agonist compounds, compositions thereof, methods of their preparation, and methods of agonizing THR beta and methods for treating disorders mediated by THR beta.
    Type: Application
    Filed: June 30, 2022
    Publication date: November 3, 2022
    Inventors: Thorsten A. KIRSCHBERG, Randall HALCOMB, Yingzi XU, F. Anthony ROMERO
  • Publication number: 20220281849
    Abstract: Provided herein are compounds, preferably thyroid hormone receptor beta (THR beta) agonist compounds, compositions thereof, and methods of their preparation, and methods of agonizing THR beta and methods for treating disorders mediated by THR beta.
    Type: Application
    Filed: August 21, 2020
    Publication date: September 8, 2022
    Inventors: Thorsten A. KIRSCHBERG, Randall HALCOMB, Yingzi XU, F. Anthony ROMERO
  • Publication number: 20220241312
    Abstract: Provided herein are prodrugs of 5-fluorodeoxyuridine monophosphate compounds, compositions thereof, methods of their preparation, and their use in treating cancers. In another aspect, provided herein is a pharmaceutical composition comprising any compound disclosed herein, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier, diluent, and excipient.
    Type: Application
    Filed: May 1, 2020
    Publication date: August 4, 2022
    Inventors: Martijn FENAUX, Weidong ZHONG, Thorsten A. KIRSCHBERG
  • Patent number: 11203587
    Abstract: Provided herein are compounds, preferably thyroid hormone receptor beta (THR beta) agonist compounds, compositions thereof, methods of their preparation, and methods of agonizing THR beta and methods for treating disorders mediated by THR beta.
    Type: Grant
    Filed: October 10, 2019
    Date of Patent: December 21, 2021
    Assignee: TERNS, INC.
    Inventors: Thorsten A. Kirschberg, Randall Halcomb, Yingzi Xu, F. Anthony Romero